Negative correlation between negative symptoms of schizophrenia and testosterone levels

Annals of the New York Academy of Sciences

Volumn 1032, Issue , 2004, Pages 291-294

  Goyal, R O ^a   Sagar, R ^a   Ammini, A C ^a   Khurana, M L ^a   Alias, A G ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b Chester Mental Health Center   (United States)

Author keywords

Schizophrenia; Testosterone

Indexed keywords

ESTRADIOL; HYDROCORTISONE; PRASTERONE SULFATE; TESTOSTERONE;

ADULT; BLOOD SAMPLING; CLINICAL ARTICLE; CONFERENCE PAPER; HORMONE BLOOD LEVEL; HUMAN; MALE; MENTAL DISEASE; PSYCHOSIS; RADIOIMMUNOASSAY; RATING SCALE; SCHIZOPHRENIA; SYMPTOMATOLOGY; TESTOSTERONE BLOOD LEVEL;

EID: 14544281889     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1314.042     Document Type: Conference Paper

References (18)

1. AKHTAR, S. & A.J. THOMSON. 1980. Scizophrenia and sexuality: a review and report of 12 unusual cases. Part II. J. Clin. Psychiatry 41: 166-174.
2. HOSKINS, R.G. 1943. Psychosexuality in schizophrenia: some endocrine considerations. Psychom. Med. 5: 3-9.
3. ALEXANDER, G.M. & B.S. PETERSON. 2001. Sex steroids and human behavior. CNS Spectrums 6: 75-88.
4. BRAMBILLA, F. 1980. Neuroendocrine function in schizophrenia. Acta Psychiatrica Belg. 80:421-435.
5. BROWN, A.S., W.C. HEMBREE, J.H. FRIEDMAN, et al. 1995. The gonadal axis of men with schizophrenia. Psychiatry Res. 57: 231-237.
6. BROPHY, M.H., J.A. RUSH & G. CROWLEY. 1983. Cortisol, estradiol, and androgens in acutley ill paranoid schizophrenics. Biol. Psychiatry 18: 583-590.
7. WALDER, D.J., E.F. WALKER & R.J. LEWINE. 2000. Cognitve functioning, cortisol release, and symptom severity in patients with schizophrenia. Biol. Psychiatry 48: 1121-1132.
8. LOOKINGBILL, O.P., L.M. DEMERS, C. WANG, et al. 1991. Clinical and biochemical parameters of androgen action in normal healthy Caucasian and Chinese men. J. Clin. Endocrin. Metab. 72: 1242-1248.
9. SILVA, P.D., E.E.K. GENTZCHEIN & R.A. LOBO. 1987. Androstenedione may be a more important precursor of tissue DHT than T in women. Fertil. Steril. 48: 419-422.
10. ZORUMSKI, C.S., S. MENNERICK, K.E. ISENBERG, et al. 2000. Potential clinical uses neuroactive steroids. I. Drugs 3: 1053-1063.
11. FRYE, C.A., K.L. EDINGER, A.M. SELIGA & J.M. WAWRZYCKI. 2004. SαR reduced androgens may have actions in the hippocampus to enhance cognitive performance of male rats. Psychoneuroendocrinology 29: 1019-1027.
12. ASADA, Y., T. SONODA, M. OJIRO, et al. 2001. 5αR type 2 is constitutively expressed in the dermal papilla and connective tissue sheath of the hair follicle in vivo but not during culture in vitro. J. Clin. Endocrin. Metab. 86: 2875-2880.
13. SHIRAYAMA, Y., K. HASHIMOTO, Y. SUZUKI & T. HIGUCHI. 2002. Correlation of plasma neurosteroid levels to the severity of negative symtoms of male patients with schizophrenia. Schizophrenia Res. 53: 69-74.
14. SANDS, D.E. 1954. Further studies in endocrine treatment in adolescence and early adult life. J. Ment. Sci. 100: 211-219.
15. MICHAEL, A., A. JENAWAY, E.S. PAYKEL, et al. 2000. Altered salivary DHEA levels in adults with major depression. Biol. Psychiatry 48: 989-995.
16. ALIAS, A.G. 1972. "Androgen dysgenesis": a predisposing factor in schizophrenia? Lancet II: 1248-1249.
17. ALIAS, A.G. 2000. Schizotypy and leadership: a contrasting model for deficit symptoms, and a possible therapeutic role for sex hormones. Med. Hypotheses 54: 537-552.
18. STROUS, R.D., R. MAAYAN, R. LAPIDUS, et al. 2003. DHEA augmentation in the management of negative, depressive and anxiety symptoms in schizophrenia. Arch. Gen. Psychiatry 60: 133-141.